Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00CTS
|
|||
| Former ID |
DAP000208
|
|||
| Drug Name |
Lubiprostone
|
|||
| Synonyms |
Amitiza; Lubiprostone [USAN]; RU 0211; RU0211; SPI 0211; SPI0211; AMITIZA (TN); RU-0211; SPI-0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic idiopathic constipation [ICD-11: DC32; ICD-10: K86, K86.1; ICD-9: 564] | Approved | [1], [2], [3], [4] | |
| Therapeutic Class |
Anticonstipation Agents
|
|||
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H32F2O5
|
|||
| Canonical SMILES |
CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F
|
|||
| InChI |
1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1
|
|||
| InChIKey |
WGFOBBZOWHGYQH-MXHNKVEKSA-N
|
|||
| CAS Number |
CAS 333963-40-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
586296, 10253236, 12015646, 14780722, 16257021, 46233438, 47206600, 50070161, 50070896, 53790069, 57348450, 75522769, 92718754, 99373600, 103771117, 104253301, 113438630, 124757421, 125164225, 126621359, 126649070, 126665948, 135113621, 139161358, 144206539, 152036058, 162037698, 162182118, 164761650, 171063061, 174528817, 174548946, 175268736, 178101059, 179150331, 196111945, 223658452, 224575239, 226571076, 247649190, 251916077, 251917425, 252215715, 252447078, 252449216, 252553475, 252562104
|
|||
| ADReCS Drug ID | BADD_D01328 | |||
| SuperDrug ATC ID |
A06AX03
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Chloride channel protein 2 (CLC-2) | Target Info | Activator | [5], [6], [7] |
| KEGG Pathway | Mineral absorption | |||
| Reactome | Stimuli-sensing channels | |||
| WikiPathways | Iron uptake and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4242). | |||
| REF 2 | 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. | |||
| REF 3 | Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011 Sep;56(9):2639-45. | |||
| REF 4 | Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. | |||
| REF 5 | Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24. | |||
| REF 6 | Expression of CLCN voltage-gated chloride channel genes in human blood vessels. J Mol Cell Cardiol. 1999 Mar;31(3):657-66. | |||
| REF 7 | Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet. 2003 Apr;33(4):527-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.